Arun P. Wiita

Dr. Arun P. Wiita

1. Department of Laboratory Medicine, University of California, San Francisco, CA, USA
+1
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2020 in Nature
Verified
Journal Article
Closed access
PDF file
XGXiaoyan Guo
Xiaoyan Guo
GAGiovanni Aviles
Giovanni Aviles
YLYi Liu
Yi Liu
RTRuilin Tian
Ruilin Tian
BUBret A. Unger
Bret A. Unger
MKMartin Kampmann
Martin Kampmann

13 January 2020 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
ALAndrew M. Leidal
Andrew M. Leidal
HHHector H. Huang
Hector H. Huang
TMTimothy Marsh
Timothy Marsh
TSTina Solvik
Tina Solvik
DZDachuan Zhang
Dachuan Zhang
JDJayanta Debnath
Jayanta Debnath

22 October 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
AGAnum Glasgow
Anum Glasgow
JGJeff Glasgow
Jeff Glasgow
Daniel LimontaDaniel Limonta
Daniel Limonta
PSPaige Solomon
Paige Solomon
ILIrene Lui
Irene Lui
JWJames A. Wells
James A. Wells
Significance: During the ongoing COVID-19 pandemic, protein engineering offers a rapid and powerful approach for building therapeutics to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. We use computational design, affinity maturation, and fusion to dimerization domains to engineer “receptor traps” based on wild-type angiotensin-converting enzyme II (ACE2), the target for viral spike-mediated SARS-CoV-2 entry into cells. The optimized ACE2 receptor traps neutralize authentic SARS-CoV-2 infections as effectively as high-affinity antibodies isolated from convalescent patients and also bind viral spike proteins from other coronaviruses known to cause respiratory diseases. ACE2 receptor traps have large binding interfaces and block the entire receptor binding interface, limiting the potential impact of viral escape mutations.

4 November 2020 in Nature
Verified
Journal Article
Open access
PDF file
JLJaewoong Lee
Jaewoong Lee
MRMark E. Robinson
Mark E. Robinson
NMNing Ma
Ning Ma
DADewan Artadji
Dewan Artadji
MAMohamed A. Ahmed
Mohamed A. Ahmed
MMMarkus Müschen
Markus Müschen
Interferon-induced transmembrane protein 3 (IFITM3) has previously been identified as an endosomal protein that blocks viral infection1,2,3. Here we studied clinical cohorts of patients with B cell leukaemia and lymphoma, and identified IFITM3 as a strong predictor of poor outcome. In normal resting B cells, IFITM3 was minimally expressed and mainly localized in endosomes. However, engagement of the B cell receptor (BCR) induced both expression of IFITM3 and phosphorylation of this protein at Tyr20, which resulted in the accumulation of IFITM3 at the cell surface. In B cell leukaemia, oncogenic kinases phosphorylate IFITM3 at Tyr20, which causes constitutive localization of this protein at the plasma membrane. In a mouse model, Ifitm3−/− naive B cells developed in normal numbers; however, the formation of germinal centres and the production of antigen-specific antibodies were compromised. Oncogenes that induce the development of leukaemia and lymphoma did not transform Ifitm3−/− B cells. Conversely, the phosphomimetic IFITM3(Y20E) mutant induced oncogenic PI3K signalling and initiated the transformation of premalignant B cells. Mechanistic experiments revealed that IFITM3 functions as a PIP3 scaffold and central amplifier of PI3K signalling. The amplification of PI3K signals depends on IFITM3 using two lysine residues (Lys83 and Lys104) in its conserved intracellular loop as a scaffold for the accumulation of PIP3. In Ifitm3−/− B cells, lipid rafts were depleted of PIP3, which resulted in the defective expression of over 60 lipid-raft-associated surface receptors, and impaired BCR signalling and cellular adhesion. We conclude that the phosphorylation of IFITM3 that occurs after B cells encounter antigen induces a dynamic switch from antiviral effector functions in endosomes to a PI3K amplification loop at the cell surface. IFITM3-dependent amplification of PI3K signalling, which in part acts downstream of the BCR, is critical for the rapid expansion of B cells with high affinity to antigen. In addition, multiple oncogenes depend on IFITM3 to assemble PIP3-dependent signalling complexes and amplify PI3K signalling for malignant transformation.

15 July 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
IFIan D. Ferguson
Ian D. Ferguson
BPBonell Patiño-Escobar
Bonell Patiño-Escobar
STSami T. Tuomivaara
Sami T. Tuomivaara
YLYu-Hsiu T. Lin
Yu-Hsiu T. Lin
MNMatthew A. Nix
Matthew A. Nix
AWArun P. Wiita
Arun P. Wiita
The myeloma surface proteome (surfaceome) determines tumor interaction with the microenvironment and serves as an emerging arena for therapeutic development. Here, we use glycoprotein capture proteomics to define the myeloma surfaceome at baseline, in drug resistance, and in response to acute drug treatment. We provide a scoring system for surface antigens and identify CCR10 as a promising target in this disease expressed widely on malignant plasma cells. We engineer proof-of-principle chimeric antigen receptor (CAR) T-cells targeting CCR10 using its natural ligand CCL27. In myeloma models we identify proteins that could serve as markers of resistance to bortezomib and lenalidomide, including CD53, CD10, EVI2B, and CD33. We find that acute lenalidomide treatment increases activity of MUC1-targeting CAR-T cells through antigen upregulation. Finally, we develop a miniaturized surface proteomic protocol for profiling primary plasma cell samples with low inputs. These approaches and datasets may contribute to the biological, therapeutic, and diagnostic understanding of myeloma.

19 February 2025 in Nature
Verified
Journal Article
Open access
PDF file
DKDarwin W. Kwok
Darwin W. Kwok
NSNicholas O. Stevers
Nicholas O. Stevers
IEInaki Etxeberria
Inaki Etxeberria
TNTakahide Nejo
Takahide Nejo
MCMaggie Colton Cove
Maggie Colton Cove
HOHideho Okada
Hideho Okada
T cell-based immunotherapies hold promise in treating cancer by leveraging the immune system’s recognition of cancer-specific antigens1. However, their efficacy is limited in tumours with few somatic mutations and substantial intratumoural heterogeneity2–4. Here we introduce a previously uncharacterized class of tumour-wide public neoantigens originating from RNA splicing aberrations in diverse cancer types. We identified T cell receptor clones capable of recognizing and targeting neoantigens derived from aberrant splicing in GNAS and RPL22. In cases with multi-site biopsies, we detected the tumour-wide expression of the GNAS neojunction in glioma, mesothelioma, prostate cancer and liver cancer. These neoantigens are endogenously generated and presented by tumour cells under physiologic conditions and are sufficient to trigger cancer cell eradication by neoantigen-specific CD8+ T cells. Moreover, our study highlights a role for dysregulated splicing factor expression in specific cancer types, leading to recurrent patterns of neojunction upregulation. These findings establish a molecular basis for T cell-based immunotherapies addressing the challenges of intratumoural heterogeneity.